DBV Technologies S.A. (DBVT)
NASDAQ: DBVT · Real-Time Price · USD
9.13
-0.04 (-0.44%)
Apr 29, 2025, 4:00 PM EDT - Market closed
DBV Technologies Revenue
In the year 2024, DBV Technologies had annual revenue of $4.15M, down -73.61%. DBV Technologies had revenue of $511.00K in the quarter ending December 31, 2024, a decrease of -94.24%.
Revenue (ttm)
$4.15M
Revenue Growth
-73.61%
P/S Ratio
57.36
Revenue / Employee
$37,736
Employees
110
Market Cap
238.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.15M | -11.58M | -73.61% |
| Dec 31, 2023 | 15.73M | 10.88M | 224.69% |
| Dec 31, 2022 | 4.84M | -864.00K | -15.14% |
| Dec 31, 2021 | 5.71M | -5.57M | -49.38% |
| Dec 31, 2020 | 11.28M | -3.43M | -23.33% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
DBVT News
- 18 days ago - DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document - GlobeNewsWire
- 4 weeks ago - DBV Technologies ADRs Rise After Up to $306.9M in New Financing - Market Watch
- 4 weeks ago - DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved - GlobeNewsWire
- 5 weeks ago - DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results - GlobeNewsWire
- 2 months ago - DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress - GlobeNewsWire
- 3 months ago - Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - GlobeNewsWire
- 4 months ago - DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids - Benzinga
- 4 months ago - DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old - GlobeNewsWire